Evidence map›Paper›PMID 42620854›Full record

SynthesisFrontiers in medicine2026

Efficacy and safety of [

Domenico Albano, Gaetano Paone, Giorgio Treglia

Abstract readSystematic Review
In one paragraph

Synthesis in Frontiers in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Domenico AlbanoNuclear Medicine, University of Brescia, Brescia, Italy.
Gaetano PaoneDivision of Nuclear Medicine, Ente Ospedaliero Cantonale, Bellinzona and Lugano, Switzerland.
Giorgio TregliaDivision of Nuclear Medicine, Ente Ospedaliero Cantonale, Bellinzona and Lugano, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) using Terbium-161 [ Methods: We conducted a comprehensive literature search across PubMed/MEDLINE, Embase, and the Cochrane databases to retrieve published articles on the efficacy and safety of [ Results: Six studies published between 2024 and 2026, including 80 mCRPC patients treated with 291 cycles of [ Conclusion: Current evidence suggests that [

Indexed as

meta-analysisnuclear medicineprostate cancerPSMAradioligand therapyTb-161

Identifiers

PMID42620854
PMCPMC13485755

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.